CINCINNATI, Nov. 25, 2011 /PRNewswire/ -- About 16 months after becoming a division of Devicor® Medical Products, Inc., Mammotome – the company that helped create and build the vacuum-assisted breast biopsy market – has made significant progress toward its new product development and growth goals.
"As the only company with a singular focus on breast biopsy, Mammotome is re-focused, re-energized, and re-committed," says CEO Tom Daulton. "We've spent more than a year solidifying our foundation for growth through product development and acquisition efforts. We're excited to start sharing new products and initiatives with the clinicians who've helped to make Mammotome the trusted, market-leading brand it is today."
With the support of a world-class, cross-functional leadership team, Daulton points to the development of next generation products and platforms as the primary driver of growth and innovation. The first of these products – a single insertion, tetherless device for use in ultrasound-guided biopsies – is currently undergoing FDA approval and is slated to be commercially available globally early next year.
In addition to preparing for next year's new products rollout, several major milestones were reached in 2011:
"We've celebrated some great accomplishments over the past year, but we do so with our eyes firmly on the future," says Daulton. "Our number one priority in every step we take along the way is to work toward our mission of developing superior, minimally-invasive tools and technologies that help clinicians best diagnose and care for their patients."
Mammotome, headquartered in Sharonville, Ohio, has more than 400 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Sold in more than 50 countries around the world, the Mammotome® product portfolio includes the Mammotome® Breast Biopsy System and tissue markers (MammoMARK®, MicroMARK®, and CorMARK®) used in breast disease diagnostic sampling and management. Since its introduction in 1995, more than 3.8 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Biopsy System. For more information, please visit www.mammotome.com.
About Devicor® Medical Products, Inc.
Devicor® Medical Products, Inc. is dedicated to building a global business through the investment in and development of tools and technologies that facilitate minimally invasive medical procedures. Under the direction of a world-class leadership team, Devicor's initial focus is on the vacuum-assisted breast biopsy market. For more information, please visit www.devicormedical.com.
Copyright©2010 PR Newswire.
All rights reserved